Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study.

Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.

Objective: PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis.

Xeligekimab: First Approval.

Xeligekimab (Jinlixi) is a recombinant human interleukin (IL)-17A-neutralizing immunoglobulin (Ig)G4 monoclonal antibody being developed by Genrix (Shanghai) Biopharmaceutical for the treatment of plaque psoriasis, axial spondyloarthritis and lupus nephritis. Xeligekimab binds to IL-17A and blocks its interaction with the IL-17A receptor, thereby inhibiting the release of C-X-C motif chemokine ligand 1 and IL-6. On 27 August 2024, xeligekimab received approval in China for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Biometrics and Biomarkers in Patients With Psoriasis.

Psoriasis (PsO) is a chronic, systemic, and autoimmune dermatologic condition characterized by dry, scaly, and erythematous plaques on the skin. PsO can present in various forms, including guttate (small, round lesions commonly over the upper trunk and extremities that can be raised and scaly), inverse (smooth plaques of inflamed skin within skin folds of the groin, buttock, and breasts), pustular (white painful pustules within red inflamed blotches widespread over the body), and erythrodermic (red rash present over most of the body). Individuals with PsO can present differently, with unique symptoms and patterns on the skin.

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.

Background: As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars have been approved.

Complicated iatrogenic Cushing's syndrome induced by topical clobetasol propionate in a child with psoriasis: a case report and review of the literature.

Background: Long-term use of oral or parenteral corticosteroids is the most common cause of hypothalamic-pituitary-adrenal axis suppression and iatrogenic Cushing's syndrome. Still, iatrogenic Cushing's syndrome occurs rarely following the administration of topical corticosteroids.

Case Presentation: This case study discusses the misuse of a high-potency corticosteroid cream by an Iranian 5-year-old male with plaque-form psoriasis, resulting in Cushingoid symptoms including moon face, buffalo hump, red striae, and weight gain.

Research progress on the pathogenesis of psoriasis and its small molecule inhibitors.

Psoriasis is a prevalent chronic systemic immune disease characterized by T-cellmediated hyperproliferation of keratinized cells. Among its various manifestations, plaque-type psoriasis is the most common. Treatment options for psoriasis encompass topical medications, biological therapies, phototherapy techniques, and others.

Rare Association of Dermatitis Herpetiformis and Chronic Plaque Psoriasis.

Dermatologists should consider investigating for coexisting autoimmune conditions such as dermatitis herpetiformis and/or coeliac disease, in patients with psoriasis presenting clinical signs and symptoms, in order to ensure an accurate diagnosis and improve patients' long-term management.

Moving cupping therapy combined with acupoint bloodletting for plaque psoriasis: A case report.

Introduction: Psoriasis is a chronic inflammatory skin disease that can present in various phenotypes, with the most common form being plaque psoriasis. Currently, no type of psoriasis can be cured, and existing treatment options are associated with certain safety concerns. In recent years, traditional Chinese medicine has achieved great results in treating psoriasis.

Long-term effectiveness and safety of deucravacitinib in psoriasis: A 52-week real-world study of genital, scalp, and nail lesions.

Background: The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp, and nail regions.

Objectives: To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp, and nail regions.

Methods: This prospective study analyzed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib.

Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada.

Background: Tildrakizumab is an interleukin-23 inhibitor approved in Canada in 2021 for the treatment of adults with moderate-to-severe plaque psoriasis.

Objectives: To evaluate real-world effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Canada.

Methods: A multicenter, retrospective study was conducted in Canada in adults with moderate-to-severe plaque psoriasis for ≥1 year treated with tildrakizumab for ≥12 weeks.

Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older.

Plaque-type psoriasis is a chronic immune-mediated inflammatory skin disease of uncertain etiology, significantly impacting patient well-being. This chronic condition not only contributes to stigmatization and mental health challenges but also poses an independent risk for cardiovascular and other comorbid diseases. Affecting approximately 60 million people globally, psoriasis manifests primarily as mild-to-moderate disease in about 80% of cases, where topical therapy is pivotal.

Psoriasis vulgaris arising on a vascular malformation in an 11-month-old female child.

While atypical, the development of psoriatic plaques over vascular malformations in children is plausible and should not necessarily prompt clinicians to perform costly or invasive procedures.

Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study.

Bimekizumab, is the most recent monoclonal antibody licensed for the management of moderate-to-severe plaque psoriasis, acting through the dual inhibition of interleukin (IL)-17 A and IL17F, setting it apart from other anti-IL17 biologics. To date, long-term data on the use of bimekizumab for the management of plaque psoriasis in a real-world setting are scant. The aim of our study was to evaluate the effectiveness and safety of bimekizumab in long-term.

Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement.

Importance: Diverse racial and ethnic representation in clinical trials has been limited, not representative of the US population, and the subject of pending US Food and Drug Administration guidance. Psoriasis presentation and disease burden can vary by skin pigmentation, race and ethnicity, and socioeconomic differences. Overall, there are limited primary data on clinical response, genetics, and quality of life in populations with psoriasis and skin of color (SoC).

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52.

Introduction: SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.

Methods: Subjects were randomized to receive 45 mg of SB17 or UST subcutaneously up to Week 40.

Silicone Breast Implants and Autoimmunity: A case report.

The impact of breast implants on the immune system has been debated since their introduction in the 1960s, linking silicone to systemic autoimmune diseases. Recent studies have shown that silicone gel can migrate from the implant capsule, triggering immune responses by proliferating immune cells and releasing cytokines, affecting T-cell function. Silicone particles can induce the release of IL-1β and activate the NALP3 inflammasome and B cells, causing an imbalance in regulatory T cells, responder T cells, and Th17 cells.

Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study.

Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current treatment options for HS are limited, as only adalimumab and secukinumab are approved for severe cases. Given the overlapping pathogenetic features between HS and psoriasis, anti-IL-17 and anti-IL-23 drugs could represent valuable treatments for the management of HS.

mTORC1 and mTORC2 Levels in Patients with Psoriasis.

Introduction: In recent years, there has been a growing emphasis on the role of the mammalian target of rapamycin (mTOR) pathway in the pathogenesis of psoriasis. This intracellular signaling pathway is known as the main control pathway of metabolism and is of particular interest in this context.

Objectives: To investigate the importance of the mTOR pathway in the pathogenesis of plaque psoriasis.

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.

Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.

Objective: The authors assessed the efficacy and safety of risankizumab compared with methotrexate in adults with moderate-to-severe plaque psoriasis.

Teriflunomide-related development of inverse psoriasis and worsening of pre-existing plaque psoriasis.

Leflunomide can be used in management of psoriatic disease. Leflunomide's active metabolite, teriflunomide, is used in the treatment of multiple sclerosis and has unexpectedly been rarely reported to induce pustular psoriasis. In this report, we present a patient with multiple sclerosis who developed inverse psoriasis after starting teriflunomide.

Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study.

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in Japan for adult patients with plaque, generalized pustular, or erythrodermic psoriasis. POETYK PSO-4 (NCT03924427), an open-label, single-arm, phase 3 trial, showed that deucravacitinib was effective and well tolerated in Japanese patients with plaque (n = 63), generalized pustular (n = 3), or erythrodermic (n = 8) psoriasis. Additional end points in POETYK PSO-4 included change measured by the patient-reported outcome measures Psoriasis Symptoms and Signs Diary and Dermatology Life Quality Index.